Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neoplasms 6 Neoplasm Metastasis 5 Melanoma 5 Carcinoma, Non-Small-Cell Lung 5 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Neoplasms by Site 3 Hereditary Sensory and Autonomic Neuropathies 3 Endometrial Neoplasms 3 Breast Diseases 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neuroblastoma 2 Multiple Endocrine Neoplasia Type 1 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Teratoma 1 Stomach Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumors 1 Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteitis Deformans 1 Neoplasms, Germ Cell and Embryonal 1

Interventions

Fulvestrant 13 Letrozole 6 Anastrozole 5 palbociclib 4 exemestane 3 Injections 3 Docetaxel 3 Paclitaxel 2 Goserelin 2 Dasatinib 2 Capecitabine 2 Alpelisib 2 AZD9833 2 vandetanib 1 ribociclib 1 irinotecan sucrosofate 1 entinostat 1 elacestrant 1 cediranib 1 abemaciclib 1 XMT-1522 1 Vinorelbine 1 Sirolimus 1 Ritonavir 1 Lead 1 Itraconazole 1 Immunotherapy, Adoptive 1 Everolimus 1 Decitabine 1 Combined Modality Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Breast Cancer × ribociclib × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡